Clinical Trials Logo
  1. Home
  2. Mature B-Cell Malignancies
  3. NCT04172246

Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

Mature B-cell Malignancies Clinical Trial

Official title:
A Phase 1/2 Study of Zanubrutinib in Japanese Patients With Mature B-Cell Malignancies

Clinical Trial Summary

This is a Phase 1/2 study of zanubrutinib in Japanese participants with mature B-cell malignancies. This study intends to assess the use of zanubrutinib as an investigational agent to develop new treatment options for Japanese participants with B-cell malignancies. No formal hypothesis testing will be performed given the small sample size.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04172246
Study type Interventional
Source BeiGene
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date January 29, 2020
Completion date September 30, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04277637 - Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies Phase 1
Active, not recruiting NCT04883957 - Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies Phase 1
Not yet recruiting NCT06351527 - Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 in Mature B-cell Malignancies Phase 1